Literature DB >> 8958301

Uterine papillary serous carcinoma evolves via a p53-driven pathway.

U M Moll1, E Chalas, M Auguste, D Meaney, J Chumas.   

Abstract

Uterine papillary serous carcinoma (UPSC) is a highly aggressive type of endometrial cancer that occurs in the absence of hyperestrogenism and endometrial hyperplasia. Biologically, UPSC belongs to a distinct group of aggressive neoplasms of the extended Müllerian epithelium that are characterized by hypoestrogenism, advanced disease at diagnosis, a serous papillary histotype, and a dismal prognosis. There is mounting evidence that loss of p53 function is critical for the molecular genetic cause of all tumors in this group. To further assess the role of p53 alterations in UPSC, we studied 40 patients using immunohistochemical expression analysis. Thirty-four tumors (85%) showed intense nuclear overexpression of p53, whereas six tumors (15%) were p53 negative. Thirteen p53-positive tumors had multiple samplings from distinct anatomic sites, and all showed complete concordance in p53 staining, suggesting that p53 alterations occur early in UPSC carcinogenesis. p53 positivity was associated with loss of hormone receptors. Thirty-nine cases were concomitantly analyzed for estrogen or progesterone receptor expression. Among those, 31 tumors were p53 positive but hormone receptor negative throughout, in contrast to only two tumors that were diffusely p53 positive and focally hormone receptor positive. Patients whose tumors overexpressed p53 had a statistically significant shorter survival than those whose tumors did not at 24 and 48 months (P = .03). This study represents one of the two largest analyses published to date that confirm the strong association between UPSC and p53 overexpression. Furthermore, we suggest that the concept of UPSC be broadened: UPSC is a p53-driven neoplasm that biologically is a kin to other serous papillary malignancies of the ovaries and peritoneum. This group of tumors bypasses the slow hormone-dependent pathway of tumorigenesis but instead undergoes early p53 alterations that lead to rapid tumor development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958301     DOI: 10.1016/s0046-8177(96)90340-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

2.  Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Authors:  Simona Stolnicu; Iulia Barsan; Lien Hoang; Prusha Patel; Luis Chiriboga; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Takako Kiyokawa; Isabel Alvarado-Cabrero; Malcolm C Pike; Esther Oliva; Kay J Park; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

3.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

4.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

5.  A case report of quadruple cancer in a single patient including the breast, rectum, ovary, and endometrium.

Authors:  Soo-Kyung Noh; Ji Yeong Yoon; Ui Nam Ryoo; Chel Hun Choi; Chang Ohk Sung; Tae Joong Kim; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

6.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

7.  Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.

Authors:  A D Santin; F Zhan; S Cane'; S Bellone; M Palmieri; M Thomas; A Burnett; J J Roman; M J Cannon; J Shaughnessy; S Pecorelli
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

8.  GNA14 silencing suppresses the proliferation of endometrial carcinoma cells through inducing apoptosis and G2/M cell cycle arrest.

Authors:  Jing Wang; Xiao Lv; Feixue Xu; Min Wei; Cuiping Liu; Yongxiu Yang
Journal:  Biosci Rep       Date:  2018-09-07       Impact factor: 3.840

Review 9.  The estrogen receptor joins other cancer biomarkers as a predictor of outcome.

Authors:  Kimberly K Leslie; Kristina W Thiel; Henry D Reyes; Shujie Yang; Yuping Zhang; Matthew J Carlson; Nirmala S Kumar; Donghai D Dai
Journal:  Obstet Gynecol Int       Date:  2013-10-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.